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Abstract: Activation of the epidermal growth factor receptor (EGFR) signaling pathway promotes the
development of hepatocellular adenoma (HCA) and carcinoma (HCC). The selective EGFR inhibitor
Gefitinib was found to prevent hepatocarcinogenesis in rat cirrhotic livers. Thus, Gefitinib might
reduce progression of pre-neoplastic liver lesions to HCC. In short- and long-term experiments,
administration of N-Nitrosomorpholine (NNM) or intrahepatic transplantation of pancreatic islets in
diabetic (PTx), thyroid follicles in thyroidectomized (TTx) and ovarian fragments in ovariectomized
(OTx) rats was conducted for the induction of foci of altered hepatocytes (FAH). Gefitinib was
administered for two weeks (20 mg/kg) or three and nine months (10 mg/kg). In NNM-treated rats,
Gefitinib administration decreased the amount of FAH when compared to controls. The amount of
HCA and HCC was decreased, but development was not prevented. Upon all transplantation models,
proliferative activity of FAH was lower after administration of Gefitinib in short-term experiments.
Nevertheless, the burden of HCA and HCC was not changed in later stages. Thus, EGFR inhibition
by Gefitinib diminishes chemical and hormonal also induced hepatocarcinogenesis in the initiation
stage in the non-cirrhotic liver. However, progression to malignant hepatocellular tumors was
not prevented, indicating only a limited relevance of the EGFR signaling cascade in later stages
of hepatocarcinogenesis.
Keywords: hepatocarcinogenesis; intraportal transplantation; epidermal growth factor receptor
(EGFR); Gefitinib
1. Introduction
Hepatocellular carcinoma (HCC) is the fifth leading cause of tumor related deaths worldwide
with increasing incidence in the Western hemisphere [1]. Main causes are chronic hepatitis B and C
virus infection, long-term alcohol abuse, aflatoxins in foodstuff, and rare inherited diseases such as
alpha-1 antitrypsin deficiency and hemochromatosis [2].
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Furthermore, hormonal influences like hyperinsulinism in type 2 diabetes mellitus and long-term
intake of oral contraceptives are risk factors for hepatocarcinogenesis in the non-cirrhotic liver [3].
The prognosis and overall survival of HCC patients is poor, with less than 5% five-year survival.
Partial resection and liver transplantation remain the only curative options, but most cases of HCC are
diagnosed in an advanced stage and are not suitable for surgical therapy. Ablation therapies, including
radio-frequency ablation, transarterial chemoembolization, and radioembolization are effective in
slowing tumor progression in advanced stages [4]. HCC is extremely resistant to conventional
chemotherapy [5]. New hopes come from the use of targeted therapies, such as receptor tyrosine
kinase inhibitors. Sorafenib (Nexavar©, Bayer, Karlsruhe, Germany) was the first (and still the only
one) of this class of new drugs to be approved by the Food and Drug Administration for the treatment
of HCC, as overall survival was improved [6].
The epidermal growth factor receptor (EGFR) is a transmembraneous protein with intrinsic
tyrosine kinase activity and belongs to the family of erbB proteins. Binding of EGF or transforming
growth factor α (TGFα) leads to receptor dimerization and autophosphorylation of the intrinsic
tyrosine kinase [7,8].
Downstream signaling cascades include the rat sarcoma/rat sarcoma-activated factor/mitogen
activated protein kinase/extracellular regulated kinase kinase (Ras/Raf/MEK/ERK) and the
phosphatidyl-inositide 3 kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/
mTOR) pathways [9]. Immunohistochemical analysis often reveals co-localization of EGFR and TGFα
in human HCC, supporting the hypothesis of autocrine and paracrine mitogenic action of TGFα to
hepatocytes [10].
Gefitinib (Iressa®, Astra-Zeneca, Wedel, Germany) is a small molecule designed to block
the catalytic domain of the EGFR tyrosine kinase, thus inhibiting downstream signaling [11].
The results of a contemporary Phase II trial approaching the adjuvant Gefitinib administration
after local ablation of HCC are still pending [12]. Applying these small molecules in models of
hepatocarcinogenesis would lead to both a deeper understanding of the molecular pathogenesis of
HCC and the evaluation of their efficacy for the treatment of this deadly disease. Continuous oral
administration of N-Nitrosomorpholine (NNM) is a well-established model of chemically-induced
hepatocarcinogenesis [13]. Earliest morphological changes in the liver are pre-neoplastic lesions
(foci of altered hepatocytes (FAH)) that are of a clear cell or mixed cell appearance, which progress to
hepatocellular adenoma (HCA) and carcinoma (HCC).
FAH can also be induced by hormonal stimuli—after intraportal transplantation of pancreatic
islets in diabetic rats (PTx, [14]), ovarian fragments in ovarectomized rats (OTx, [15]) and thyroid
follicles in thyroidectomized rats (TTx, [16]). After low-number islet transplantation, insulin related
alterations lead to glycogen and fat storing clear cell foci downstream of the islet transplant, which
evolve into basophilic foci and progress to HCA and HCC [14]. The hepatocytes downstream
of the transplanted ovarian fragments are characterized by an amphophilic phenotype driven by
estrogens [17], which also evolve to HCA and HCC [15]. Intraportal transplantation of thyroid
follicles and the influence of triiodothyronine (T3) lead to hyperproliferative FAH downstream of
the transplants, which are amphophilic-tigroid [16]. T3 is a direct mitogen for hepatocytes without
preceding cell loss [18]. By contrast to the other models, a progression to HCA or HCC could not be
seen in long term experiments after thyroid follicle transplantation.
Overexpression of TGFα is documented in NNM induced hepatocarcinogenesis [19] and
pre-neoplastic lesions of PTx and OTx transplantation models [14,15], but not in T3 induced
hepatocellular alterations [16].
Therefore, we investigated the antitumoral effect of Gefitinib in rat models of chemically-induced
hepatocarcinogenesis (administration of NNM) and three different intraportal transplantation models
of hormonal active tissue (PTx, OTx or TTx), with particular regard to early pre-neoplastic lesions
(in the case of NNM, insulin and estrogens, respectively), and hyperproliferative hepatocellular
alterations (in the case of triiodothyronine, T3).
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2. Results
2.1. Hepatocellular Lesions after N-Nitrosomorpholine (NNM) Administration
FAH were induced in all animals that received NNM for three months, and mainly consisted of
clear cell foci, whereas HCA or HCC were not observed at this time point. After six months of NNM
administration, multiple HCA and HCC were detected in all NNM-treated rats (Figure 1).
2.1.1. Proliferative Activity
After three months of NNM administration, FAH of all NNM groups exhibited a three-fold higher
BrdU-LI than the extrafocal liver tissue. Gefitinib treatment did not affect the proliferation rate in rats.
After six months of NNM administration and Gefitinib therapy for three months, proliferative activity
of FAH was slightly reduced compared to animals without Gefitinib treatment (BrdU-LI of NNM six
months alone 85.50% ± 1.90%; NNM six months, Gefitinib three months 70.36% ± 1.75%; p < 0.05).
BrdU-LI was not altered in HCA or HCC (Table 1).
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Figure 1. Effects of Gefitinib at six months after administration of N-Nitrosomorpholine (NNM) and 
expression patterns of epidermal growth factor receptor (EGFR), transforming growth factor α 
(TGFα) and downstream signaling in pre-neoplastic foci of altered hepatocytes (FAH) and 
neoplastic liver lesions. Gefitinib was administered daily for three months (10 mg/kg) (A); Glycogen 
storing foci of altered hepatocytes (FAH) after NNM administration (NNM 6 months) with an 
overexpression of EGFR and TGFα, which is reduced after Gefitinib treatment for three months 
(NNM 6 months & 3 months), implying downregulation of proteins of dependent signaling 
pathways of phosphatidyl-inositide 3 kinase/protein kinase B/mammalian target of rapamycin 
(PI3K/AKT/mTOR) (p-mTOR and phosphorylated 4E-binding protein 1 (p-4EBP1)) and rat 
sarcoma/rat sarcoma-activated factor/mitogen activated protein kinase/extracellular regulated kinase 
kinase (Ras/Raf/MEK/ERK) (Ras and PanERK) pathways, corresponding to less proliferative activity 
and volume fraction of FAH in Gefitinib treated rats (B). After six months of NNM administration 
(NNM 6 months), hepatocellular adenomas (HCA) and carcinomas (HCC) reveal a strong of TGFα, 
to a lesser extent of EGFR. Gefitinib treatment for two weeks or three months (NNM (6 months & 2 
weeks)/(6 months & 3 months)) does not alter protein expression levels. Immunostaining scores are 
shown in brackets. Arrows correspond to ↑ upregulation, ↓ downregulation or ↔ unchanged 
expression level. Expression levels of immunostaining are given in brackets. Magnification: (A) 
overview 40×; marked lesion in dashed lines (PAS and immunostainings) 100×; and (B) (H & E and 
immunostainings) 100×; marked area in dashed lines (EGFR) 400×. 
  
Figure 1. Effects of Gefitinib at six months after administration of N-Nitrosomorpholine (NNM) and
expression patterns of epidermal growth factor receptor (EGFR), transforming growth factor α (TGFα)
and downstream signaling in pre-neoplastic foci of altered hepatocytes (FAH) and neoplastic liver
lesions. Gefitinib was administered daily for three months (10 mg/kg) (A); Glycogen storing foci of
altered hepatocytes (FAH) after NNM administration (NNM 6 months) with an overexpression of EGFR
and TGFα, which is reduced after Gefitinib treatment for three months (NNM 6 months & 3 onths),
implying downregulation of proteins of dependent signaling pathways of phosphatidyl-inositide
3 kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) (p-mTOR and
phosphorylated 4E-binding protein 1 ( -4EBP1)) and rat sarcoma/rat sarcoma-activated factor/mitogen
activated protein kinase/extracellular regulated kinase kinase (Ras/Raf MEK/ERK) (Ras and PanERK)
pathways, corresponding to less proliferative activity and volume fraction of FAH in Gefitinib treated
rats (B). After six months of NNM administr tion (NNM 6 months), hepatocellular adenomas (HCA)
and carcin mas (HCC) rev al a strong f TGFα, to a lesser extent of EGFR. Gefitinib treatment for two
week or three m nths (NNM (6 months & 2 weeks)/(6 months & 3 months)) does not alter protein
expression levels. Immunostaining scores re shown brackets. Arrows correspond to ↑ upregulation,
↓ downregul tion or↔ unchanged expression level. Expression levels of immunostaining are given in
brackets. Magnification: (A) ov rview 40×; marked lesion in dash d lines (PAS and immunostainings)
100×; and (B) (H & E and immuno tainings) 100×; marked area in dashed lines (EGFR) 400×.
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Table 1. The effect of gefitinib treatment on the proliferative activity of pre-neoplastic liver lesions
and extrafocal liver tissue (a); proliferative activity (b); and quantity (c) of hepatocellular tumors in
chemical hepatocarcinogenesis with N-Nitrosomorpholine.
Duration of NNM
Administration
Gefitinib
Administration N BrdU-LI FAH, %
BrdU-LI Extrafocal
Liver Tissue, %
3 months 7 68.26 ± 6.82 § 18.07 ± 2.72
3 months 2 weeks HD 7 60.80 ± 2.80 § 18.33 ± 2.88
3 months 3 months LD 7 55.49 ± 3.00 § 12.53 ± 1.29
(a)
Duration of NNM
Administration
Gefitinib
Administration N BrdU-LI FAH %
BrdU-LI
HCA %
BrdU-LI
HCC %
6 months 6 85.50 ± 1.90 89.73 ± 1.13 97.14 ± 0.32
6 months 2 weeks HD 7 73.89 ± 3.17 81.03 ± 2.70 95.49 ± 0.82
6 months 3 months LD 7 70.36 ± 1.75 # 76.03 ± 1.75 92.67 ± 1.58
(b)
Duration of NNM
Administration
Gefitinib
Administration N
Volume
Fraction FAH %
Volume
Fraction HCA %
Number of
HCC per
Animal
3 months 14 7.25 ± 0.90 - -
3 months 2 weeks HD 14 4.92 ± 0.87 # - -
3 months 3 months LD 15 1.58 ± 0.28 # - -
6 months 12 85.86 ± 0.67 10.36 ± 0.89 7.93 ± 0.92
6 months 2 weeks HD 15 84.82 ± 0.83 10.51 ± 0.56 6.53 ± 1.61
6 months 3 months LD 15 88.01 ± 0.57 # 5.43 ± 0.57 # 4.87 ± 0.77 #
(c)
Rats were subjected to daily administration of NNM (5 mg/kg body weight). Gefitinib was administered
daily and orally for two weeks (HD, high dose of 20 mg/kg) or three months and nine months, respectively
(LD, low dose of 10 mg/kg). BrdU was administered for the duration of one week before sacrifice via an osmotic
minipump. Data are expressed in percent (mean ± SEM). N—number of evaluated animals. BrdU-LI—BrdU
labeling index; FAH—foci of altered hepatocytes; HCA—hepatocellular adenoma; HCC—hepatocellular
carcinoma. § p < 0.05 vs. extrafocal liver tissue; # vs. untreated controls.
2.1.2. Volume Fraction of FAH and HCA
After NNM administration for three months, FAH foci occupied a reduced volume portion of
liver parenchyma after two weeks Gefitinib with 4.92 ± 0.87 vol % and after three months with
1.58 ± 0.28 vol % as compared to administration of NNM alone (7.25 ± 0.90 vol %; p < 0.05).
After six months, volume fraction of FAH was not reduced after Gefitinib treatment. A halving of
volume portion of HCA from 10.36 ± 0.89 vol % to 5.43 ± 0.57 vol % could be instead appreciated
(p < 0.05). The number of HCC was reduced from 7.93 ± 0.92 to 4.87 ± 0.77 tumors per animal
(p < 0.05) (Table 1).
2.2. Hepatocellular Lesions in Transplantation Models
2.2.1. Short Term Experiments
Intraportal transplantation of pancreatic islets, ovarian fragments, and thyroid follicles resulted in
the development of FAH in the transplanted rats (Figures 2A, 3A, 4A). In particular, typical clear cell
foci—demonstrated by the PAS reaction—developed after islet transplantation, whereas amphophilic,
glycogen-depleted foci occurred after transplantation of ovarian fragments, and amphophilic-tigroid
cell foci followed the transplantation of thyroid follicles. FAH exhibited increased proliferative activity
in comparison to unaltered extrafocal liver tissue. The proliferative activity of FAH was reduced
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upon all transplantation models after administration of high-dose Gefitinib (20 mg/kg body weight).
Indeed, the BrdU-LI was approximately halved in the Gefitinib-treated groups (Gefitinib treatment
vs. untreated: PTx six months 2.27% ± 0.13% vs. 6.06% ± 0.49%, p < 0.05; OTx three months:
12.67% ± 2.67% vs. 29.79% ± 2.68%, p < 0.05; TTx three months: 7.69% ± 1.07% vs. 12.25% ± 1.33%,
p < 0.05). Gefitinib administration had almost no effect on proliferation of unaltered hepatocytes in the
extrafocal liver parenchyma (Table 2).
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Figure 2. Effects of Gefitinib after intraportal transplantation of pancreatic islets in diabetic rats 
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weeks and six months). FAH (dashed lines) of untreated rats (PTx 3 weeks and 6 months) at the 
downstream level of transplanted islets (*) with glycogen storage (PAS) with a slight overexpression 
of EGFR and TGFα. After Gefitinib treatment for two weeks (PTx 3 weeks & 2 weeks), only TGFα is 
upregulated. Nevertheless, downstream signaling with representative p-mTOR, p-4EBP1, Ras, and 
PanERK is downregulated corresponding to less proliferative activity after Gefitinib administration. 
By contrast, at six months (PTx (6 months & 2 weeks)/(6 months & 3 months)), signaling is 
upregulated or not altered respectively, suggesting resistance to Gefitinib; (B) Long-term 
experiments (12 and 24 months). After 12 months, expression levels of EGFR or TGFα are higher in 
FAH (dashed lines, with islets (*)) after Gefitinib treatment in comparison to untreated rats. After 24 
months, hepatocellular carcinomas with overexpression of EGFR and TGFα, which is almost not 
reduced after Gefitinib treatment; (C) The SGLT1 glucose transporter is expressed in FAH of 
untreated PTx rats. There is no difference after Gefitinib treatment. Immunostaining scores are 
shown in brackets. Arrows correspond to ↑ upregulation, ↓ downregulation or ↔ unchanged 
expression level. Expression levels of immunostaining are given in brackets. Magnification: (A) 3 
weeks/(3 weeks & 2 weeks) (H & E and PAS) 40×; marked area in dashed lines (immunostainings) 
400×; 6 months/(6 months & 2 weeks)/(6 months & 3 months) (H & E, PAS) 200×; marked areal in 
dashed line (immunostainings) 400×; (B) 12 months/(12 months & 2 weeks) (H & E and PAS) 60×; 
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Figure 2. Effects of Gefitinib after intraportal transplantation of pancreatic islets in diabetic rats
(PTx) and expression patterns of EGFR, TGFα, downstrea signaling pathways and the glucose
transporter protein Sodium-glucose cotransporter 1 (SGLT1) in pre-neoplastic foci of altered hepatocytes
(FAH) and neoplastic liver lesions. Gefitinib was administered daily for two weeks (20 mg/kg body
weight) or nine months (10 g/kg), respectively. (A) Short-term experiments (three weeks and
six months). FAH (dashed lines) of untreated rats (PTx 3 weeks and 6 months) at the downstream
level of transplanted islets (*) with glycogen storage (PAS) with a slight overexpressi n of EGFR and
TGFα. After Gefitinib treatment for two weeks (PTx 3 weeks & 2 weeks), only TGFα is upregulated.
Nevertheless, downstr am signaling with representativ p-mTOR, p-4EBP1, Ras, and PanERK is
downregulated corresponding to less proliferative activity after Gefitinib administration. By contrast,
at six mon hs (PT (6 months & 2 weeks)/(6 months & 3 months)), signaling is upregulated or not
altered respectively, sugg sting istance to Gefitinib; (B) Long-term experiments (12 and 24 months).
Aft 12 months, expression levels of EGFR or TGFα are higher in FAH (dashed lines, with islets
(*)) after Gefitinib treatment in comparison to un reated rats. After 24 months, hepatocellular
carcinomas with overexp ession of EGFR and TGFα, which is almost not reduced after Gefitinib
treatment; (C) The SGLT1 glucose transporter is expressed in FAH of untr ated PTx rats. There
is no difference after Gefitinib treatment. Immunostai ing scores are show in bracket . Arrows
correspond to ↑ upregulation, ↓ downregulation or↔ unchanged expression level. Expression lev ls
of immunostaining are give in brackets. Magnification: (A) 3 w eks/(3 week & 2 weeks) (H & E and
PAS) 40×; marked area in dashed lines (immunostainings) 400×; 6 months/(6 months & 2 weeks)/
(6 months & 3 months) (H & E, PAS 200×; marked areal in dashed line (immunost inings) 400×;
(B) 12 months/(12 months & 2 weeks) (H & E and PAS) 60×; marked area in ashed line
(immunost inings) 400×; 24 months/(24 months & 9 months) overview 20×; marked area in dashed
lines (H & E nd immunostai ings) 400×; (C) (H & E and SGLT1) 400×.
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Short-term experiments (three months). FAH of untreated rats (OTx 3 months) at the downstream 
level of transplanted ovarian fragments reveal loss glycogen storage (PAS) and a slight 
overexpression of EGFR and TGFα and also of downstream signaling with representative p-mTOR 
and PanERK, p-4EBP1 and Ras. After Gefitinib treatment for two weeks (OTx 3 months & 2 weeks), 
the EGFR and TGFα but not downstream signaling are slightly reduced; (B) Long-term experiments 
(12 and 24 months). Transplant tumors and associated FAH with unaltered EGFR but 
downregulated TGFα expression level after Gefitinib treatment for two weeks (OTx 12 months & 2 
weeks) in comparison to untreated rats (OTx 12 months). Small HCAs (*) with upregulation of the 
EGFR and TGFα after Gefitinib treatment for 9 months (OTx 24 months & 9 months). 
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Figure 3. Effects of Gefitinib after intraportal transplantation of ovarian fragments in ovariectomized
rats (OTX) and expression patterns of EGFR, TGFα and downstrea signaling pathways in
pre-neoplastic foci of altered hepatocytes (FAH) and neoplastic liver lesions. Gefitinib was administered
daily for two weeks (20 mg/kg body weight) or 9 months (10 g/kg), respectively. (A) Short-term
experiments (three months). FAH of untreated rats (OTx 3 months) at the downstream level of
transplanted ovarian fragments reveal loss glycogen storage (PAS) and a slight overexpression of
EGFR and TGFα and also of downstream signaling ith representative p-mTOR and PanERK, p-4EBP1
and Ras. After Gefitinib treatment for two weeks (OTx 3 months & 2 weeks), the EGFR and TGFα
but not downstream sig aling are slightly reduced; (B) Long-term experiments (12 and 24 months).
Transplant tu ors and associated FAH with unaltered EGFR but downregulated TGFα expression
level after G fitinib treatm nt for two weeks (OTx 12 months & 2 weeks) in comparison to untreated
rats (OTx 12 months). Small HCAs (*) with upregulation of the EGFR and TGFα after Gefitinib
treatment for 9 months (OTx 24 mon hs & 9 months). Immunostaining scores are hown in brackets.
Arrows correspond t ↑ upregulation, ↓ downregulation o ↔ unchanged expression lev l. Expression
levels of immun staini g re giv n in brackets. Magnification: (A) 3 months/(3 months & 2 weeks)
(H & E) 40×; marked area in das ed lines (PAS and immunostainings) 600×; (B) 12 months/
(12 months & 2 weeks) (H & E) 4 ×; marked area in dashed line (H & E and immunostainings)
400×; 24 months/(24 mo ths & 9 mo ths) (H & E) 100×; marked area in dashed lines
(immunostainings) 400×.
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Figure 4. Effects of Gefitinib at three months after intraportal transplantation of thyroid follicles
fragments in thyroidectomized rats (TTx) and expression patterns of EGFR and TGFα and downstream
signaling pathways in pre-neoplastic foci of altered hepatocytes (FAH) and neoplastic liver lesions.
Gefitinib was administered daily for nine months (10 mg/kg). (A) Short-term experiments. FAH of
untreated rats (TTx 3 months) at the downstream level of transplanted thyroid follicles reveal loss
glycogen storage (PAS). There is no overexpression of EGFR and TGFα or of downstream signaling
with representative p-mTOR, p-4EBP1, Ras and PanERK. After Gefitinib treatment for two weeks
(TTx 3 months & 2 ee s), the EGFR and TGFα expression and downstream signaling is also ot
upregulated and thus not ltered; (B) Long-term experime ts (24 months). Transplanted follicles (*)
and associated hepatocellular adenoma with strong overexpr ssion of EGFR and TGFα of untreated
rat (TTx 24 months) in comparison to treated rat (TTx 24 months & 9 months) with d wnregulation of
EGFR and TGFα. Im u ostaining sc res are show in brackets. Arrows correspond to ↑ upregulation,
↓ downregul tion or↔ unchanged expression level. Expression levels of immu ostaining are given
in brackets. Magnification: (A) 3 months/(3 m nths & 2 w eks) (H & E) 40×; marked area in dashed
lines (PAS and immunostainings) 600×; (B) 24 months/(24 months & 9 months) (H & E) 40×; marked
area in dashed line H & E and immunostainings) 400×.
Int. J. Mol. Sci. 2016, 17, 1618 10 of 18
Table 2. The effect of gefitinib treatment on the proliferative activity of pre-neoplastic liver lesions and
extrafocal liver tissue in hormonal hepatocarcinogenesis.
Treatment
Procedure Time after Tx
Gefitinib
Administration N BrdU-LI FAH %
BrdU-LI Extrafocal
Liver Tissue, %
PTx 3 weeks 4 10.7 ± 0.99 § 3.48 ± 0.77
3 weeks 2 weeks HD 4 5.74 ± 0.49 § 1.25 ± 0.26
6 months 5 6.06 ± 0.44 § 1.17 ± 0.08
6 months 2 weeks HD 6 2.27 ± 0.13 §,# 0.60 ± 0.03 #
6 months 3 months LD 6 3.55 ± 0.22 § 0.74 ± 0.04
12 months 5 2.43 ± 1.39 0.35 ± 0.27
12 months 2 weeks HD 9 1.26 ± 0.44 § 0.09 ± 0.05
12 months 3 months LD 7 1.55 ± 0.51 0.49 ± 0.20
24 months 4 10.50 ± 6.94 6.69 ± 2.80
24 months 9 months LD 3 19.20 ± 5.82 5.33 ± 3.78
OTx 3 months 7 29.79 ± 2.68 § 2.66 ± 0.39
3 months 2 weeks HD 6 12.67 ± 2.64 §,# 2.67 ± 1.59
12 months 6 16.52 ± 2.47 § 5.68 ± 0.10
12 months 2 weeks HD 7 8.73 ± 0.88 §,# 5.12 ± 0.94
12 months 3 months LD 4 13.55 ± 2.50 6.29 ± 0.49
24 months 6 6.50 ± 1.56 2.26 ± 0.58
24 months 9 months LD 5 11.10 ± 1.77 6.35 ± 5.22
TTx 3 months 7 12.25 ± 1.33 § 2.84 ± 0.53
3 months 2 weeks HD 8 7.69 ± 1.07 # 6.61 ± 1.63 #
12 months 8 11.04 ± 1.45 § 1.07 ± 0.18
12 months 2 weeks HD 6 11.36 ± 1.55 § 0.69 ± 0.28
12 months 3 months LD 6 10.62 ± 1.91 § 2.31 ± 1.08
24 months 7 9.33 ± 2.67 § 1.58 ± 0.90
24 months 9 months LD 9 6.34 ± 1.23 § 1.13 ± 0.33
Proliferative activity foci of altered hepatocytes (FAH) and extrafocal tissue, determined as BrdU labeling index
(BrdU-LI) after intraportal transplantation of pancreatic islets (PTx), ovarian fragments (OTx) or thyroid follicles
(TTx) at different time points and with or without administration of gefitinib (HD, high dose of 20 mg/kg body
weight, LD, low dose of 10 mg/kg body weight). N—number of evaluated animals. BrdU was administered
via an osmotic pump for a duration of one week before sacrifice. p < 0.05 § vs. extrafocal liver tissue, # vs.
untreated controls.
2.2.2. Long Term Experiments
Administration of high dose Gefitinib for two weeks before sacrifice could significantly reduce
the proliferative activity only in FAH from the OTx model after 12 months (8.73% ± 0.88% vs.
16.52% ± 2.47%, p < 0.05, Table 3). Low dose treatment with Gefitinib for three months or nine
months before sacrifice did not influence the proliferation rate of FAH or extrafocal liver tissue in
the three transplantation models in 12 and 24 months experiments. Frequency and quantity of FAH
did not differ between treated and untreated groups. Transplant associated HCA arose in all three
transplantation models after 12 and 24 months post-transplantation without Gefitinib as well as after
high (two weeks prior to sacrifice) or low dose (three or nine months before sacrifice) Gefitinib treatment
(Figures 2B, 3B, 4B). In general, 12 months after transplantation, HCA occurred most frequently in PTx
livers. After 24 months, HCA could also be detected in OTx and TTx animals. Transplant associated
HCC arose very seldom and only after 24 months after transplantation in PTx and OTx animals without
and with high dose of Gefitinib. Hyperplasia of transplants developed often after OTx and transplant
tumors in some cases after TTx, in untreated and Gefitinib-treated rats at both time points. Transplant
tumors of TTx livers mainly revealed follicular or papillary morphology with mild to moderate atypia;
in one case (24 months, without Gefitinib), criteria for a thyroid carcinoma with invasive growth and
high mitotic activity were applicable (Table 3).
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Table 3. The effect of gefitinib treatment on the frequency of hepatocellular tumors in hormonal
hepatocarcinogenesis.
Treatment
Procedure Time after Tx
Gefitinib
Administration
Rats with
HCA Rats with HCC
Rats with Transplant
Hyperplasia or Tumors
PTx 12 months 16 (34) 0 (34) 0
12 months 2 weeks HD 8 (17) 0 (17) 0
12 months 3 months LD 11 (17) 0 (17) 0
24 months 5 (19) 1 (19) 0
24 months 9 months LD 3 (10) 1 (10) 0
OTx 12 months 0 (15) 0 (15) 3 (15)
12 months 2 weeks HD 1 (16) 0 (16) 6 (16)
12 months 3 months LD 1 (16) 0 (16) 7 (16)
24 months 9 (20) 1 (20) 10 (20)
24 months 9 months LD 9 (21) 1 (21) 12 (21)
TTx 12 months 1 (15) 0 (15) 0 (15)
12 months 2 weeks HD 2 (14) 0 (14) 1 (14)
12 months 3 months LD 2 (13) 0 (13) 1 (13)
24 months 3 (15) 0 (15) 2 (15)
24 months 9 months LD 8 (15) 0 (15) 2 (15)
Frequency of transplant associated hepatocellular adenomas (HCA), carcinomas (HCC) and transplant
hyperplasia or tumors after intraportal transplantation of pancreatic islets (PTx), ovarian fragments (OTx)
or thyroid follicles (TTx) at different time points and with or without administration of gefitinib (HD, high dose
of 20 mg/kg body weight, LD, low dose of 10 mg/kg body weight). The number of investigated animals is
given in parentheses.
2.3. Effects of Gefitinib on Expression Levels of EGFR, TGFα and Downstream Effectors in Different
Hepatocarcinogenesis Models
EGFR and TGF-α are upregulated in pre-neoplastic FAH, HCA and HCC induced after NNM
(Figure 1) administration and after PTX (Figure 2) and OTx (Figure 3) in untreated rat livers
in comparison to extrafocal liver tissue, whereas TTx (Figure 4) induced lesions revealed no
overexpression. Representative downstream target proteins of the AKT/mTOR and MAPK signaling
pathways (p-mTOR, p-4EBP1, Ras and PanERK) were also strongly activated, as expected, in NNM
and PTx induced FAH, and also after OTx, but are not detectable after TTx.
Gefitinib treatment for three months reduced the expression levels of EGFR and TGFα in FAH
of six months treated NNM rats, thus correlating with less proliferative activity and volume fraction
of FAH in Gefitinib treated rats. Nevertheless, levels of AKT/mTOR and MAPK cascades were not
altered in hepatocellular tumors (Figure 1).
While EGFR expression is not altered and TGFα is predominantly upregulated in the PTx
model after administration of Gefitinib, the downstream AKT/mTOR and MAPK pathways were
downregulated, corresponding to less proliferative activity in short time experiments. By contrast,
at six months and Gefitinib treatment for two weeks/three months, downstream cascades were not
altered or even upregulated, suggesting the resistance to Gefitinib. In long-term PTx experiments
of 12 and 24 months, expression levels of EGFR or TGFα were also higher in FAH after Gefitinib
treatment, as it has been detected in short-term experiments. HCCs showed strong overexpression of
EGFR and TGFα, which was almost not reduced after Gefitinib treatment. Additional assessment of
the transporter protein sodium/glucose cotransporter 1 (SGLT1), whose expression increases following
EGFR inactivation [20] revealed cytoplasmatic and slight membranous expression in FAH of untreated
PTx rats, which was not altered after Gefitinib treatment (Figure 2).
In early FAH, which are related to transplanted ovarian fragments of the OTX model, the EGFR
and TGFα and also downstream signaling of MAPK and AKT/mTOR were found to be slightly
upregulated, which could be only slightly diminished after Gefitinib treatment in three months and
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12 months experiments. Thus, reduction of proliferative activity of FAH cannot be attributed to this
signaling pathway inhibition, as epatocellular neoplasms, such as HCA after 24 months, also reveal
upregulation of the EGFR and TGFα after Gefitinib treatment (Figure 3).
Early hepatocellular proliferative lesions of the TTx model did not express the EGFR, TGFα or
downstream target proteins, neither without nor after Gefitinib administration (Figure 4). Upregulation
in hepatocytes could only be seen in one animal at the downstream level in one animal with a malignant
transplant tumor, and thus a single observation (not shown).
3. Discussion
Hepatocarcinogenesis is accompanied by overexpression of multiple growth factors and activation
of various signaling pathways, including EGF, Vascular endothelial growth factor (VEGF), Insulin like
growth factor (IGF), MAPK, PI3K/AKT/mTOR, and Wnt/β-Catenin [21–26]. They might represent
valuable targets for systemic molecular-based therapies. EGFR is expressed in most HCC [10,27], and
EGFR inhibitors such as the monoclonal antibody cetuximab or tyrosine kinase inhibitors such as
Gefitinib and Erlotinib are able to suppress HCC growth both in vitro and in vivo [9,28,29].
In this study, we investigated the antiproliferative and antitumoral activity of the EGFR
tyrosine kinase inhibitor Gefitinib in various models of hormonally- and chemically-induced
hepatocarcinogenesis.
In the NNM model, representing chemical hepatocarcinogenesis without contemporary liver
cirrhosis, selective EGFR inhibition by Gefitinib diminished hepatocarcinogenesis at the level of
initiation (early time points) and progression (later time points), as the volume fraction of pre-neoplastic
liver lesions and HCAs and the number of HCC were reduced. These results are supported by former
findings of Gefitinib effects on sequential cirrhosis and HCC development in diethylnitrosamine treated
rats [30], which was interpreted as a chemopreventive option for HCC development. Interestingly,
EGFR inhibition by Gefitinib did not influence proliferative activity in NNM induced FAH, but the
amount of pre-neoplastic and neoplastic tissue was reduced, accompanied by downregulation of the
EGFR and TGFα expression levels and reduction of related protooncogenic signaling. Furthermore,
the antitumoral effect of Gefitinib might be directed toward cells other than hepatocytes. In accordance
with the latter hypothesis, it has been shown that Gefitinib administration leads to the inhibition of
angiogenesis due to apoptosis induction in endothelial cells and decreased production of proangiogenic
molecules in pancreatic cancer [31].
The protooncogenic signaling pathways of AKT/mTOR and Ras/raf-1/MAPK, which are
activated in the NNM and the PTx [32–34], could also be substantiated to be slightly upregulated after
OTx, but not after TTx. At the initiation level of FAH (short time experiments) inhibition of the EGFR
by Gefitinib could reduce proliferative activity corresponding to a diminished downstream signaling
in FAH after PTx and OTx.
On the contrary, Gefitinib administration did not influence proliferative activity of FAH or
the development of hepatocellular neoplasms at the progression level in long-term experiments.
Furthermore, downstream signaling pathways were upregulated after Gefitinib administration,
suggesting resistance mechanisms in hepatocytes. One has to consider that, due to severe side effects,
Gefitinib must be administered at a low dose in long-term experiments, which might partly explain
the lack of inhibition of liver tumor development in the various models examined. Nevertheless,
resistance to Gefitinib in the late stages of hepatocarcinogenesis is very likely and has been described
in the treatment of human non-small-cell lung cancer as well [35] and in HCCs of diethylnitrosamine
treated rats [30].
Possible resistance of the AKT/mTOR and Ras/raf-1/MAPK oncogenic signaling pathways
to EGFR tyrosine kinase inhibitors has been described [30,36]. Activation of these pathways by
other growth factor receptors like Hepatocyte growth factor/c-Met, IGF-1R and the Insulin receptor
could explain the emergence of residual tumors [37–41]. Furthermore, other members of the erb-B
receptor family, which are also upregulated in human HCC [22], might also drive hepatocarcinogenesis.
The effect of Gefitinib to these receptors remains poorly understood.
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Lately, Steinway [37] found that the EGFR pathway acts as a compensatory survival mechanism
upon c-Met inhibition in human c-Met-positive HCC, and combined inhibition of both c-Met and
EGFR oncogenic pathways provides superior suppression of HCC tumor growth.
We could substantiate an upregulation of the sodium/glucose cotransporter 1 (SGLT1) in FAH
of PTX rats after Gefitinib treatment, another possible explanation of resistance with unrestrained
proliferation and cell growth. SGLT1 maintains high intracellular glucose levels leading to cell survival
and intracellular homeostasis, is activated by EGFR independent of its kinase activity, and is therefore
not influenced by tyrosine kinase inhibitors [20].
Furthermore, our findings of upregulation of the EGFR expression levels, mainly in liver lesions
after PTx, illustrate resistance to Gefitinib after long term application. Nevertheless, this paradoxical
conversion of EGFR expression cannot be explained by direct effects of Gefitinib, as its target is
only the catalytic domain of the EGFR tyrosine kinase [11] with inhibition of downstream signaling.
Mechanisms of transactivation of the EGFR by other activated receptors in hepatocarcinogenesis,
as has been shown for the Insulin-Like Growth Factor Receptor 1 (IGF-1R) in Erlotinib treated HCC
cell lines Huh7 [42], would be a possible explanation.
In this study, some HCA could be detected after intraportal transplantation of thyroid
follicles (TTx) for the first time in this experimental setting, as manifest hepatocellular
neoplasms have not been described by Dombrowski et al. [16]. Despite one simple HCA near
a transplant tumor after TTx, neither the EGFR nor the TGFα were upregulated in hormonal
induced alterations of hepatocytes after TTx. Nevertheless, Gefitinib treatment induced a
reduction of proliferative activity, suggesting that T3 induced pathways in hepatocytes, like the
nuclear thyroid hormone receptor activation or related enzyme activities of i.e., cyclooxygenases,
glucose-6-phosphatase or glucose-6-phosphat-dehydrogenase [16], are influenced by Gefitinib,
independently of its EGFR-activity.
4. Experimental Section (for Details Refer to Supplementary Materials and Methods)
4.1. Animal Treatments
Seven hundred sixty-eight inbred male and female Lewis rats (3 months old, 150–250 g) were used
in the present study. Housing of the animals was described in detail previously [14–16]. The animal
protocols used in this work were evaluated and approved by the Committee for Animal Research
(Protocol no. LALLF M-V/TSD/7221.3-1.1-023/08, 15 April 2008) and in the accordance with the
German Animal Protection Law.
Animals were allocated to four different experimental settings to the chemical model of
hepatocarcinogeneses after administration N-Nitrosomorpholine (NNM) or to three established
intraportal transplantation models and to appropriate control groups, as shown in Table 4.
Table 4. Experimental design of investigated models of hepatocarcinogenesis.
Treatment
Procedure
Sacrifice
Time Point
Gefitinib
Administration N
Sacrifice
Time Point
Gefitinib
Administration N
Experimental
groups
Control
groups
PTx (male) 3 weeks - 8 male 3 weeks - 10
3 weeks 2 weeks HD 12 3 weeks 2 weeks HD 10
6 months - 10 3 months - 15
6 months 2 weeks HD 14 3 months 2 weeks HD 15
6 months 3 months LD 12 3 months 3 months LD 15
12 months - 34 6 months - 26
12 months 2 weeks HD 17 6 months 2 weeks HD 25
12 months 3 months LD 17 6 months 3 months LD 25
24 months - 19 12 months - 11
24 months 9 months LD 10 12 months 2 weeks HD 10
12 months 3 months LD 10
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Table 4. Cont.
Treatment
Procedure
Sacrifice
Time Point
Gefitinib
Administration N
Sacrifice
Time Point
Gefitinib
Administration N
TTx (male) 3 months - 15 24 months - 19
3 months 2 weeks HD 15 24 months 9 months LD 24
12 months - 15
12 months 2 weeks HD 14 female 3 months - 10
12 months 3 months LD 13 3 months 2 weeks HD 10
24 months - 15 12 months - 14
24 months 9 months LD 15 12 months 2 weeks HD 9
12 months 3 months LD 9
OTx
(female) 3 months - 15 24 months - 21
3 months 2 weeks HD 15 24 months 9 months LD 17
12 months - 15
12 months 2 weeks HD 16
12 months 3 months LD 16
24 months - 20
24 months 9 months LD 21
NNM 3 months - 15
3 months 2 weeks HD 15
3 months 3 months LD 15
6 months - 15
6 months 2 weeks HD 15
6 months 3 months LD 15
Overview of all investigated experimental and control groups in short (3 weeks, and 3 and 6 months) and
long term investigations (12 and 24 months) after intraportal transplantation of pancreatic islets (PTx), ovarian
fragments (OTx) or thyroid follicles (TTx) or administration of N-Nitrosomorpholine (NNM) at different sacrifice
time points (time after transplantation or beginning of NNM administration) and with or without administration
of gefitinib (HD, high doses of 20 mg/kg body weight, LD, low doses of 10 mg/kg body weight) as indicated.
N number of animals in respective groups.
4.2. Administration of NNM
Male Lewis rats were fed NNM (Sigma Aldrich, Darmstadt, Germany) orally in a low dose
(5 mg/kg body weight) daily throughout the experiment.
4.3. Transplantation Models
4.3.1. Diabetes Induction and Intraportal Pancreatic Islet Transplantation (PTx)
Diabetes was induced by streptozotocin (80 mg/kg body weight) prior to the intraportal
transplantation of 400–450 pancreatic islet grafts.
4.3.2. Thyroidectomy and Intraportal Transplantation of Thyroid Follicles (TTx)
Rats were thyroidectomized before intraportal transplantation of isolated, isologous thyroid
tissue pieces.
4.3.3. Ovariectomy and Intraportal Transplantation of Ovarian Fragments (OTx)
Female, ovariectomized rats received isolated, isologous grafts of small fragments of
ovarian tissue.
4.3.4. Control Groups
Male and female Lewis rats, non-diabetic, not ovariectomized or thyroidectomized and without
transplantation procedures or NNM administration were either given Gefitinib as the experimental
groups or left untreated.
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4.3.5. Gefitinib Treatment
Gefitinib (Iressa®, Astra Zeneca, Wedel, Germany) was administered daily and orally for two
weeks (with 20 mg/kg) or three and nine months, respectively (with a reduced dose of 10 mg/kg),
to respective groups as shown in Table 1.
4.3.6. Application of the Nucleoside Analog 5-Bromo-2′-deoxyuridine (BrdU)
Seven days before sacrifice, osmotic minipumps (Osmotic Pump Model 2ML1, Alzet, Alza Corp.,
Palo Alto, CA, USA) filled with 40 mg of BrdU (Sigma Aldrich, Heidelberg, Germany) were implanted
in one third of the animals of each group.
4.3.7. Animal Sacrifices and Tissue Processing
Rats were sacrificed at 3 weeks, 3 months, 6 months, 12 months and 24 months, respectively, post
transplantation. After perfusion fixation, the liver was removed and cut into slices of 1–2 mm thickness.
All macroscopically visible lesions (>2 mm) and additional 10 liver slices were embedded in paraffin.
Slides of 2–3 µm thickness were cut and stained by H&E and the periodic acid Schiff (PAS) reaction.
4.3.8. Immunohistochemistry
Formalin-fixed, paraffin-embedded or frozen tissue serial sections were stained for TGF-α,
EGFR, BrdU, sodium-glucose-transporter protein 1 (SGLT1), phosphorylated mTOR (p-mTOR),
phosphorylated 4 eukaryotic translation initiation factor 4E binding protein 1 (p-4EBP1), Ras, and
extracellular related kinase (PanERK).
4.3.9. Morphologic Investigations
FAH in different models were classified according to Bannasch and Zerban [43] into glycogen
storing foci, basophilic foci, amphophilic foci, and amphophilic-tigroid cell foci [16]. Furthermore,
frequency and amount of transplant associated HCAs, HCCs and hyperplastic transplants or
transplant tumors, respectively, were assessed. BrdU labeling indices (BrdU-LI) and volume fraction
determination in hepatocellular lesions and extrafocal liver tissue were determined as described
earlier [14,44]. Expression levels of immunostaining were scored as product of % of hepatocytes (factors
of 0 = 0%; 1 = 1%–<10%; 2 = 10%–<75%; 3 = 75%–100%) and intensity of membranous/cytoplasmatic
staining result (0 = no staining; 1 = weak; 2 = medium; 3 = strong). A product difference between
groups of ≥2 was defined as upregulation or downregulation, respectively.
4.4. Statistical Analysis
The Wilcoxon–Mann–Whitney U test was applied to determine differences regarding the BrdU-LIs
in intraindividual and interindividual comparisons and in cell proliferation assays. Differences
regarding the number of tumor bearing animals were assessed via Fisher’s exact test. p-Values of less
than 0.05 were considered statistically significant.
5. Conclusions
EGFR inhibition by Gefitinib also diminishes chemical and hormonal induced
hepatocarcinogenesis at the level of initiation in the non-cirrhotic liver, as quantity and proliferative
activity of different types of pre-neoplastic liver lesions are decreased. By contrast, progression to
neoplastic hepatocellular tumors, even if reduced in the NNM model, is not prevented. This indicates
only a partial relevance of the EGFR signaling pathway in later stages of hepatocarcinogenesis, where
multiple oncogenic pathways are known to be activated, but should be considered for combined
therapy with conventional cytostatic drugs or other targeted agents.
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